Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease.

[1]  Richard D Moore,et al.  The Effect Of Buprenorphine On HIV Viral Suppression. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  R. Rossom,et al.  Prevalence and Medication Treatment of Opioid Use Disorder Among Primary Care Patients with Hepatitis C and HIV , 2021, Journal of General Internal Medicine.

[3]  Saeed Ahmed,et al.  Microinduction of Buprenorphine/Naloxone: A Review of the Literature. , 2020, The American journal on addictions.

[4]  K. Humphreys,et al.  Steep increases in fentanyl-related mortality west of the Mississippi River: Recent evidence from county and state surveillance , 2020, Drug and Alcohol Dependence.

[5]  J. Rich,et al.  One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission. , 2020, Journal of substance abuse treatment.

[6]  G. Oyler,et al.  Protracted renal clearance of fentanyl in persons with opioid use disorder. , 2020, Drug and alcohol dependence.

[7]  E. Strain,et al.  Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone. , 2020, The American journal on addictions.

[8]  F. Boland,et al.  Retention of patients in opioid substitution treatment: A systematic review , 2020, PloS one.

[9]  E. Nunes,et al.  A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder , 2019, The American journal of drug and alcohol abuse.

[10]  S. Martins,et al.  "Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl. , 2019, The International journal on drug policy.

[11]  J. Gryczynski,et al.  Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder. , 2019, Drug and alcohol dependence.

[12]  M. Spencer,et al.  Regional Differences in the Drugs Most Frequently Involved in Drug Overdose Deaths: United States, 2017. , 2019, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[13]  A. Janowsky,et al.  Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[14]  P. Seth,et al.  Changes in Opioid-Involved Overdose Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and Methamphetamine — 25 States, July–December 2017 to January–June 2018 , 2019, MMWR. Morbidity and mortality weekly report.

[15]  N. Rigotti,et al.  Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence. , 2019, Journal of addiction medicine.

[16]  A. Bisaga.  What should clinicians do as fentanyl replaces heroin? , 2019, Addiction.

[17]  Marie A Abate,et al.  Fentanyl and fentanyl-analog involvement in drug-related deaths. , 2019, Drug and alcohol dependence.

[18]  M. Olfson,et al.  Development of a Cascade of Care for responding to the opioid epidemic , 2019, The American journal of drug and alcohol abuse.

[19]  T. Kosten,et al.  Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. , 2018, Drug and alcohol dependence.

[20]  L. Mancl,et al.  A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment , 2018, The American journal of drug and alcohol abuse.

[21]  E. Nunes,et al.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial , 2017, The Lancet.

[22]  P. Korthuis,et al.  Feasibility and safety of extended‐release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial , 2017, Addiction.

[23]  M. Pavlicova,et al.  Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine. , 2017, The American journal of psychiatry.

[24]  E. Nunes,et al.  Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice , 2012, The American journal of drug and alcohol abuse.

[25]  Bianca L. De Stavola,et al.  Gformula: Estimating Causal Effects in the Presence of Time-Varying Confounding or Mediation using the G-Computation Formula , 2011 .

[26]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[27]  R. D. Bruce,et al.  HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study , 2011, Journal of acquired immune deficiency syndromes.

[28]  Richard D Moore,et al.  Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment Program , 2010, Annals of Internal Medicine.

[29]  K. Lynch,et al.  Initial evidence for the reliability and validity of a "Lite" version of the Addiction Severity Index. , 2007, Drug and alcohol dependence.

[30]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[31]  A. Sandler,et al.  A review of the use of fentanyl analgesia in the management of acute pain in adults. , 1999, Anesthesiology.

[32]  J. Silverstein,et al.  An Analysis of the Duration of Fentanyl and Its Metabolites in Urine and Saliva , 1993, Anesthesia and analgesia.